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INTRODUCTION
Malignant gliomas, one of the most common primary brain
tumors, are very aggressive tumors with poor prognosis des-
pite a multi-modality treatment approach including surgery,
radiotherapy and chemotherapy. The median survival time
of patients with glioblastoma multiforme (GBM) is 5-12
months from the diagnosis and it increases to 11-36 months
for anaplastic astrocytoma (AA) (1). Unfortunately, the stan-
dard chemotherapy of nitrosoureas or procarbazine-based
regimens has only modest activity and significant toxicity
when used in the setting of recurrent malignant gliomas.
Therefore, there is considerable interest in new chemothera-
py agents such as temozolomide (2).
Temozolomide is a new orally administerable, second-gen-
eration imidazotetrazine prodrug with an essentially 100%
oral bioavailability. Pre-clinically, temozolomide demonstrates
a broad spectrum, schedule dependent, antitumor activity
with relatively little toxicity. Temozolomide spontaneously
converts to the active alkylating agent 5-(3-methyltriazen-1-
yl) imidazole-4-carboximide under physiological conditions
with extensive tissue distribution, including a penetration of
the blood-brain barrier and into the cerebrospinal fluid (3). 
Numerous studies have demonstrated the activity of temo-
zolomide against malignant brain tumors, particularly chemo-
resistant malignant gliomas (4). Recently, studies have been
focusing on the development of strategies to optimize the
clinical efficacy of temozolomide by different dosing sched-
ules and combination of other antineoplastic agents. How-
ever, no study of temozolomide effect for malignant gliomas
has been reported in an Asian population. Here, the authors
analyzed a single institution’s experience of temozolomide
chemotherapy for the patients with recurrent or progressive
malignant glioma after surgery and standard radiation ther-
apy with or without chemotherapy. 
MATERIALS AND METHODS
Eligible criteria 
Eligible patients were over 17 yr old, had a histologically
proven malignant glioma (GBM, AA, anaplastic oligoden-
droglioma) according to the WHO criteria and unequivocal
evidence of a tumor recurrence or progression by the any of
following imaging modalities: gadolinium magnetic reso-
nance imaging (Gd-MRI); contrast-enhanced computerized
tomography (CT) scanning after surgery and standard radia-
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Temozolomide Chemotherapy in Patients with Recurrent Malignant
Gliomas 
Numerous studies have demonstrated the clinical activity of temozolomide, a sec-
ond-generation alkylating agent, against malignant brain tumors, however, its activity
has not been reported in an Asian population. This study analyzed the efficacy and
toxicity of temozolomide in 25 adult patients with recurrent or progressive malignant
gliomas after surgery and standard radiation therapy with or without chemotherapy,
enrolled in our institution since July 2000. Sixteen patients had glioblastoma multi-
forme (GBM), six with anaplastic astrocytoma, and three with anaplastic oligoden-
droglioma. Of the 25 patients, 3 (12%) achieved a complete response (CR), 8 (32%)
achieved a partial response (PR), 6 (24%) had stable disease (SD), and 8 (32%)
had progressive disease (PD). Two patients achieved a CR, 4 patients achieved a
PR, 3 patients had SD and 7 patients had PD in GBM, and 1 patient achieved a
CR, 4 patients achieved a PR, 3 patients had SD, 1 patient had PD in the non-GBM
patients. Median progression free survival was 8 weeks in GBM and 22 weeks in
the non-GBM patients. The median overall survival of each group was 17 weeks
and 28 weeks. Temozolomide demonstrated moderate activity in recurrent and
progressive malignant gliomas without serious toxicity.
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tion therapy with or without chemotherapy (at least 4 weeks
apart from the completion of previous chemotherapy or radio-
therapy). Other eligibility criteria included the following: a
Karnofsky performance of at least 60 or more and a life expec-
tancy of more than 12 weeks at the beginning of the temo-
zolomide therapy; adequate hematological, hepatic and renal
function; and patient provided written informed consent. The
baseline characteristics of all the patients were summarized
(Table 1).
Treatment plan
Temozolomide was administered orally at a dosage of 150
mg/m2/day (750 mg/m2total dose per cycle) on day 1 through
5 to the fasting patients who had received previous chemo-
therapy or at a dosage of 200 mg/m2/day (1,000 mg/m2 total
dose per cycle) for patients who had not received previous
chemotherapy. The treatment cycles were repeated every 28
days until neurological or radiological deterioration developed.
The patients were asked to fast four hours prior to and two
hours after administration. A full blood examination was
performed prior to each new cycle. 
Response evaluation
The responses were evaluated according to Macdonald’s
criteria (5). The first follow up MRI was performed after 2-3
cycles and the next one after 4-6 cycles. A complete response
(CR) was defined as the complete disappearance of all the
enhancing or non-enhancing tumors or edema on the MRI
(excluding calcification, or MRI T2 periventricular or white
matter abnormalities not in continuity with the known tumor
mass), with an improvement or stable neurological status
without corticosteroid requirements. A partial response (PR)
was defined as a greater than 50% decrease in the tumor size,
with an improvement or stability in the neurological status.
Progressive disease (PD) was defined as a 25% or greater
increase in tumor size, the appearance of new lesions, or a
progressive neurological decline not explained radiographi-
cally and not attributable to any other cause. Stable disease
(SD) was defined as a less than 50% regression or less than
25% increase in the tumor size, with stable neurological sta-
tus and a stable or declining corticosteroid requirement.
Statistical analysis
Progression-free survival time (PFS) was estimated from the
start of temozolomide to tumor progression or to the moment
of being withdrawn from the study, and overall survival (OS)
from the start of temozolomide to the date of death, irrespec-
tive of its cause, or to the last evaluation. PFS and OS were
assessed by the product-limit method of Kaplan-Meier for
all 25 patients.
RESULTS
Response 
From July 2000 to April 2004, 25 patients were evaluable.
The median number of treatment cycles was 4 (range 1-15)
and the median follow-up period was 15 months (range 2-
40 months). 
Table 2 summarizes the response rates to treatment. In 16
GBM patients, 2 (12.5%) patient achieved a CR, 4 (25%)
patients achieved a PR, and 3 (18.8%) patients had SD. The
No.
Age
(yr)
Sex Pathology Treatment
Surgical
procedure
Interval*
(months)
Temozo-
lomide
cycles
1 59 M GBM S+RT T 4 1
2 62 F GBM S+RT+CTx T 5 4
3 33 F GBM S+RT B 29 1
4 43 F GBM S+RT+CTx T 36 9
5 28 F GBM S+RT+CTx P 20 6
6 19 M GBM S+RT+CTx T 72 2
7 57 M GBM S+RT T - 2
8 61 F GBM S+RT B 2 12
9 43 F GBM S+RT+CTx T 3 2
10 44 M GBM S+RT T 13 2
11 64 F GBM S+RT+CTx P 3 5
12 46 M GBM S+RT+CTx T 7 1
13 44 F GBM S+RT+CTx T 7 9
14 61 M GBM S+RT T 8 6
15 24 F GBM S+RT+CTx T 52 7
16 62 F GBM S+RT T 5 2
17 45 M AO S+RT+CTx P 103 3
18 49 F AA S+RT+CTx B 4 15
19 48 F AA S+RT+CTx P 41 5
20 64 M AA S+RT+CTx B 4 3
21 40 F AA S+RT+CTx P 31 6
22 28 F AO S+RT+CTx P 17 3
23 24 F AA S+RT+CTx B 11 3
24 18 F AA S+RT P 9 4
25 47 M AO S+RT+CTx P 31 7
Table 1. Patients characteristics (n=25)
S, Surgery; RT, Radiotherapy; CTx, Chemotherapy; T, Total removal; P,
Partial removal; B, Biopsy. 
*Interval between radiotherapy and temozolomide chemotherapy.
All patients
(n=25)
GBM
(n=16)
AA and AO
(n=9)
Complete response 3 (12%) 2 (12.5%) 1 (11%)
Partial response 8 (32%) 4 (25%) 4 (44.4%)
Stable response 6 (24%) 3 (18.8%) 3 (33.3%)
Progressive disease 8 (32%) 7 (43.8%) 1 (11%)
Table 2. Response to temozolomide chemotherapy
GBM, glioblastoma multiforme; AA, anaplastic astrocytoma; AO, ana-
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overall response rate (CR+PR+SD) was 56.3% (Fig. 1). In
the 9 non-GBM patients, there were 4 patients with PR (44.4
%), 1 patient with a CR (11%) and 3 patients with SD (33.3
%). the overall response rate was 88.7% (Fig. 2).
Survival 
The median progression-free survival of the GBM patients
and the non-GBM patients were 8 and 22 weeks, respectively
(Fig. 3). The median overall survival of each group was 17
weeks and 28 weeks.
Toxicity 
Toxicity grading and dose modification were based on the
National Cancer Institute Toxicity Criteria (6). Table 3 sum-
marizes the toxicity data. Nausea and vomiting of grade 1
occurred in 7 patients and was well controlled using standard
antiemetics. One patient, who had suffered from the hepatic
parenchymal disease before the temozolomide chemothera-
py, developed hepatic toxicity of grade 2. Seizures developed
in one patient who was on valproic acid. There was no treat-
ment related mortality.
DISCUSSION
The recurrence of malignant gliomas is associated with sig-
nificant morbidity and limited survival. Most patients have
already received multimodality therapies including surgery,
radiotherapy and, on occasion, chemotherapy, at the initial
diagnosis. Generally, radiotherapy cannot be administered
upon a recurrence, and thus the therapeutic options are lim-
ited to a further resection or palliative chemotherapy. Pallia-
tive chemotherapy has previously been considered to have a
modest efficacy in a recurrent setting. These chemotherapeu-
tic agents do not often result in meaningful clinical improve-
ments and are associated with significant toxicity. In contrast,
recent studies have suggested that temozolomide is relatively
active in this setting and is well tolerated. Furthermore, the
oral formulation of temozolomide is likely to be more accept-
able to patients than intravenous regimens.
This study demonstrated significant activity of the drug,
with a 68% overall response rate (complete, partial response
and stable disease). The notion that stable disease constitutes
‘a response’ is not generally accepted in the oncology field.
However, achieving stable disease in the context of malignant
gliomas has been shown to have significant prognostic effects.
This results support other studies using temozolomide in
recurrent malignant gliomas. The efficacy of temozolomide
in high-grade gliomas has been evaluated in phase II studies
Fig. 1. Pre-chemotherapy MR image (A) and MR image after three courses of temozolomide (B) of a patient with a grade 4 glioma, consis-
tent with a partial response.
A B
No. (%) of
Grade 
1 (%)
Grade 
2 (%)
Grade 
3 (%)
Grade 
4 (%)
Leukopenia 3 (12) 1 (4) 0 0
Thrombocytopenia 0 0 0 0
Nausea/vomiting 7 (28) 0 0 0
Hepatic 2 (8) 1 (4) 0 0
Table 3. Toxicity according to National Cancer Institute Toxicity
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in patients at the initial relapse. In a multicenter CRC phase
II study, patients with recurrent or progressive high-grade
glioma were treated with temozolomide as a first-line thera-
py. The objective response rate (complete response and par-
tial response) was 11% with a median survival of 5.8 months
(7). A similar response rate (8%) and median survival (5.4
months) were observed in a second multicenter phase II trial
of temozolomide in a glioblastoma (8). The imaging response
rate was 6% and the median survival was 12.4 weeks in a
temozolomide arm of a randomized phase II study compar-
ing temozolomide with procarbazine (9). In a phase II study
of patients with anaplastic astrocytomas at the initial relapse,
the objective response rate to temozolomide was 35% (10).
Nevertheless, other studies have suggested that temozolomide
improves time to progression and the quality of life but not
the overall survival (11-14).
Myelosuppression is the most serious adverse effect of temo-
zolomide, and is dose limiting. However, it does not appear
to be cumulative and relatively easily treated. In this study,
temozolomide treatment was extremely well tolerated with
few significant side effects. Nausea and vomiting were mild
and could be well controlled in most cases using standard
antiemetics. This study concurs with other studies of temo-
zolomide in which serious side effects were uncommon. In
an open label phase II study reported by Brada et al. (8) in
glioblastoma multiforme, only 3 out of 132 patients evalu-
ated discontinued therapy because of the adverse events. Grade
3/4 myelosuppression occurred in only 12% of the 414 che-
motherapy cycles. Yung et al. (10) reported that only 9 out
of 158 anaplastic astrocytoma patients (6%) evaluated discon-
Fig. 2. Pre-chemotherapy MR image (A) showing ill-defined lesion
involving the posterior portion of the corpus callosum of a patient
with a grade 3 glioma. Non-enhanced CT scan (B) and enhanced
CT scan (C) after fourteen cycles of temozolomide, consistent
with a complete response. 
A B
Ctinued treatment due to the adverse events. Of these patients,
6 discontinued treatment after 6 cycles of therapy. The most
frequent adverse events, nausea and vomiting (49%), were
readily controlled by standard antiemetics. Other toxicities
included fatigue (25%), constipation (23%), and headaches
(13%). Interestingly, seizures newly developed in one patient
who was on valproic acid even though the drug level was
within the therapeutic range and follow-up imaging study
showed the decrease in the tumor size with a stablility in
the neurological status. It is not clear which factor could be
related to the seizure, such as radiation effect or interaction
between temozolomide and antiepileptic drugs.
The difficulties in evaluating the response to therapeutic
interventions in primary brain tumors are highlighted by
this study. The effect of temozolomide in patients who have
undergone prior radiotherapy has yet to be established (15).
It is plausible that prior radiotherapy should affect the patient’s
response to temozolomide. In this study, the mean time inter-
val between radiotherapy and temozolomide was 21.5 months
(range 2-103 months) and eligible patients developed recur-
rences even after conventional radiotherapy was completed.
It remains unclear how much the later effect of radiotherapy
is involved in the response including the temozolomide che-
motherapy. Another unresolved issue is the treatment dura-
tion. We continued the treatment cycles until the progres-
sion or for a maximum of 15 cycles. No cumulative toxic
effects or late effects of exposure to an alkylating agent were
observed, but the number of patients exposed to long-term
therapy is very small. Assessing the activity of new drugs in
brain tumors is a difficult task, because measuring of response
rates according to the conventional criteria may not reflect
the real clinical benefit. New endpoints require a prospec-
tive validation and should be supported by a quality-of-life
analysis (16, 17). 
Overall, temozolomide is a new reasonably well tolerable
and active oral chemotherapeutic agent for treating malignant
gliomas. It has established its place as standard of care for
the treatment of recurrent malignant glioma. Future studies
may incorporate a combination regimen with other chemo-
therapeutic agents in both recurrent and adjuvant settings
(18). Stupp et al. (19, 20) demonstrated that concomitant
radiotherapy plus continuous daily temozolomide therapy
followed by additional cycles of the standard regimen of adju-
vant temozolomide therapy was well tolerated and may pro-
long the survival in patients with malignant glioma.
Primary temozolomide chemotherapy or chemoradiother-
apy for treating metastatic brain tumors is currently under
investigation. In addition, the responses to temozolomide
have been reported in non-small cell lung cancer, primary
central nervous system lymphoma and melanoma (15).
Assessing the true efficacy of temozolomide will require a
larger study with a comparison with other agents and treat-
ment modalities.
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